, on Friday finished a £7.48 million private placing to further the clinical development of Clevegen®.
Dr Markku Jalkanen, CEO of Faron, commented: "This financing will allow us to further progress our clinical programme on Clevegen with a view to clarifying its full potential, either alone or in combination with existing cancer treatments.”
Faron’s MATINS trial showed that Clevegen® promoted immune activation in patients, potentially making it a new and effective macrophage immune checkpoint drug for cancer patients.
Dr. Jalkanen said: “This is very important as many, if not all, cancer patients have reduced immune capacity to defend them against cancer spread and may potentially be focal information in terms of specifying our goals for the ongoing partnering discussions."
Shares in Faron were trading 10.47% higher at 237.5p after the fundraise
Shares in Faron have risen by about 350% year to date.
3,935,500 shares were placed at 190p, representing about 10% of Faron’s issued share capital before the placing.
Faron told investors that the proceeds are expected to provide twelve months of working capital.
The company is to advance Clevegen, initiating the cohort expansion of the MATINS trial in colorectal cancer, eventually sharing the data with the US FDA to discuss a biologics licence application.
It is also having a face-to-face meeting with the FDA in early December to discuss Traumakine, its phase III treatment for acute respiratory distress.
Faron also welcomed the significant number of new Nordic shareholders after the placing, after Swedish firm Carnegie Investment Bank AB acted as financial adviser and bookrunner.
Follow News & Updates from Faron Pharmaceuticals here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
(Sharecast News) - London equity markets finished in positive territory on Friday, managing to break above the waterline in late trading after worries about rising Covid-19 cases and further restrictions knocked sentiment earlier in the session.
Find out in this fascinating 25mins interview, what super-smart UK smallcap fund manager Judith MacKenzie (Downing) thinks of today's equity markets, along with discussing her investment process and 5 compelling deep value/GARP stock ideas.
Bahamas Petroleum, the Caribbean and Atlantic margin focused oil and gas company has announced announce that the Stena IceMAX drill rig for the upcoming Perseverance #1 drilling campaign is expected to be on site around the 15 December. This means that Perseverance #1 would be expected to spud prior to Christmas 2020.
Prospex Energy PLC, the AIM quoted investment company, Half Year Report highlights the advancing portfolio of late stage onshore European gas projects that range from exploration through to power generation. Once the Company has achieved first gas at Selva in Italy and the transfer of a 49.9% interest in the El Romeral gas and power project to our Spanish affiliate, the Company assures investors Prospex will be a highly cash flow generative energy investment company.
(Sharecast News) - London stocks edged higher in early trade on Friday as investors mulled over the latest UK borrowing figures, but the FTSE 100 was still on course for heavy weekly losses amid ongoing concerns about the coronavirus and its impact on the economy.